| INTRODUCTION
Despite the known benefits of good glycemic control, 1, 2 achieving it in children and adolescents with diabetes can be extremely challenging due to a complex mix of lifestyle factors and the physiological and developmental changes (eg, development of insulin resistance during puberty) that occur as they mature. 3 The International Society for Pediatric and Adolescent Diabetes (ISPAD) guidelines recommend that pediatric patients receive basal-bolus therapy to allow titration of individual insulin doses 4 ; however, this regimen is complex, which can negatively impact treatment adherence. 5, 6 A third of adolescents with type 1 diabetes (T1D) report omitting insulin doses. 7 In addition, concern surrounding hypoglycemia 8 can cause reluctance to titrate insulin therapy appropriately. This can leave children with T1D at risk of suboptimal glucose control which may have detrimental effects on brain development. 9, 10 Treatments with a more physiological action profile are needed to minimize variation in insulin action and mimic endogenous insulin more closely. Current premixed formulations are not ideal in this respect due to an extended effect of the prandial component, caused by interference between the bolus and prandial components.
11
The ISPAD guidelines acknowledge that premixed analog insulins, commonly used in some countries, may help to reduce the number of injections when adherence is a problem. 4 Insulin degludec/insulin aspart (IDegAsp) is a soluble, ready-to-use co-formulation in the ratio 70% insulin degludec (IDeg) to 30% insulin aspart (IAsp). It is the first co-formulation of basal and bolus insulin that retains the individual pharmacokinetic/pharmacodynamic characteristics of its components, with IDeg providing long-acting insulin coverage and IAsp providing short-acting insulin action. 12 In contrast, available premixed formulations require resuspension. 13, 14 Inadequate resuspension prior to injection decreases dosing precision and increases variability in absorption kinetics, which may increase day-to-day variability in glycemic control. 15 This study aimed to assess the efficacy and safety of IDegAsp administered OD plus IAsp for remaining meals compared with a full basal-bolus regimen in a pediatric population with T1D.
2 | METHODS
| Trial conduct
This was a 16-week, phase 3b, treat-to-target, multinational, multicen- Children and adolescents (1-<18 years of age) with T1D, previously treated with any insulin regimen for ≥3 months at a total daily insulin dose of ≤2 U/kg, and with glycosylated hemoglobin (HbA1c) levels of ≤11% (≤96.7 mmol/mol), were eligible for inclusion ( Figure S1 ).
| Randomization
A central interactive voice/web response system was used to randomize eligible participants 1:1 to receive either IDegAsp (100 U/mL, Penfill 3-mL cartridge, Novo Nordisk A/S, Denmark) or IDet (100 U/mL, Penfill 3-mL cartridge; Novo Nordisk), both with mealtime IAsp (100 U/mL, Penfill 3 mL cartridge; Novo Nordisk). Randomization was stratified according to three age groups: 1-<6, 6-<12 and 12-<18 years to ensure an approximately equal distribution of individuals in these different age groups between treatment arms.
| Procedures
Trial duration, including screening and follow-up visits, was approxi- Once-weekly titration of IDegAsp OD and IDet OD was conducted according to the lowest prebreakfast SMPG value measured on the 3 days prior to the visit/phone contact. For IDet BID, the morning dose adjustment was based on the lowest predinner SMPG value measured on the 3 days prior to the visit/phone contact. During the trial, the IDegAsp dose could be switched from one meal to another for safety or efficacy reasons at the investigator's discretion. 
| Statistical methods
Statistical analyses were carried out for efficacy endpoints derived after 16 weeks of treatment, and included all randomized participants (full analysis set [FAS] ), following the intention-to-treat principle.
Safety endpoints were summarized using the safety analysis set (all randomized participants exposed to at least one dose of investigational product). Sample size was determined based on the noninferiority evaluation, using a t-statistic assuming a one-sided test of size 2.5%, a zero mean treatment difference and SD of 1.25%. Secondary efficacy end-points were analyzed with a MMRM similar to that applied to the primary end-point, with corresponding baseline values included as covariate.
As prespecified in the trial protocol, P-values were only determined for the primary end-point. The other end-points were considered supportive and explorative in nature.
Hypoglycemic events were modeled using negative binomial regression, with a log-link function and the logarithm of the time period for which a hypoglycemic episode was considered treatment emergent as offset. The model included treatment, sex, region, and age group as fixed factors.
Body weight was expressed as descriptive SD scores, derived from the participant's age, sex, and body weight together with country-specific reference growth curves (or US Centers for Disease
Control and Prevention data where unavailable).
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3 | RESULTS
| Patient characteristics
The participant flow is summarized in Figure 1 . In total, 362 participants were randomized to receive either IDegAsp + IAsp (n = 182) or IDet + IAsp (n = 180); one participant from the IDegAsp + IAsp group withdrew consent prior to exposure and one withdrew from the IDet + IAsp group due to randomization in error. Demographics and baseline characteristics were similar across treatment and age groups, apart from some differences in mean FPG and mean duration of diabetes (Table 1 ). Therapies at screening were: basal-bolus insulin ther- [0.91; 1.14] 95%CI ).
| Insulin dose
Insulin doses at weeks 1 and 16 are given in The mean number of injections per day at the end of the trial was 3.6 for IDegAsp + IAsp, and 4.9 for IDet + IAsp (post hoc analysis; P < 0.0001), using Wilcoxon two-sample test.
In terms of adherence to titration protocol, prescribed minus actual dose was similar between treatment groups. Figure 3A and Table 3 (Table S1 ).
| Hypoglycemia
Rates of confirmed nocturnal hypoglycemia were similar between treatment groups (IDegAsp + IAsp: 5.77, and IDet + IAsp: 5.40 episodes/patient-year) ( Figure 3B and Table 3 ), and were highest in the oldest age group in both treatment groups ( Figure S6 ). Rates of noc- 
| Hyperglycemia with ketosis
The rate of hyperglycemic episodes was similar for IDegAsp + IAsp 
| Change in body weight
Analysis of change from baseline in weight SD score showed a statisti- 
| Adverse events
AE profiles were similar for IDegAsp + IAsp and IDet + IAsp (Table 4 ).
The majority of reported AEs for both groups were mild or moderate in severity and resolved by the end of the trial. Except for hypoglycemia, the most commonly reported AEs in both treatment groups were headache, nasopharingitis, upper abdominal pain, pyrexia, and vomiting (Table S2 ). The observed rate of serious AEs (SAEs) was low, although numerically higher in the IDegAsp + IAsp treatment group than with IDet + IAsp (14 vs 7 events; 0.26 vs 0.13 events/patientyear) (Table 4) . One participant in the IDegAsp + IAsp group withdrew from the trial due to an AE (hypoglycemic seizure) and one participant in the IDet + IAsp group withdrew due to "other" safety reasons "intermittent but recurrent hypoglycemia attributed to trial product." The overall rate of nocturnal confirmed hypoglycemia was highest in the oldest age group (12-<18 years old). This may be attributed to the adolescent lifestyle, as this population tends to be more active than the younger age groups during the period defined as "nocturnal"
(23:00-07:00) in this study.
Similar to the results reported by Thalange et al, 28 who investigated the safety and efficacy of IDeg OD in a pediatric trial of similar design, we observed a numerical reduction in the rates of hyperglycemia with ketosis with IDegAsp + IAsp vs IDet + IAsp; however, this difference did not reach statistical significance.
At baseline, patients in the IDegAsp treatment group had a numerically longer mean diabetes duration and slightly higher FPG, overall.
The effect of this on outcomes is unclear but it is unlikely to impact results since (1) the differences are not substantial and (2) randomization was stratified by the three different age groups and differences in FPG and diabetes duration were not observed for all three age groups.
Limitations of this trial include its open-label design and its short duration, which was based on ethical considerations and phase 3a data available for adults with T1D or T2D at the time of trial design. Novo Nordisk and Medtronic for scientific meetings. Ma.K. has nothing to declare. N.S. has received honoraria for lectures and advisory board participation from Novo Nordisk. A grant was made from Novo
Nordisk to NS's hospital for patient education.
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